Frazier Life Sciences Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q1 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 10,109,279 shares of PHAT stock, worth $104 Million. This represents 5.64% of its overall portfolio holdings.
Number of Shares
10,109,279
Previous 10,109,279
-0.0%
Holding current value
$104 Million
Previous $92.3 Million
16.32%
% of portfolio
5.64%
Previous 5.68%
Shares
3 transactions
Others Institutions Holding PHAT
# of Institutions
123Shares Held
54.7MCall Options Held
34KPut Options Held
58.7K-
Medicxi Ventures Management (Jersey) LTD7.46MShares$76.9 Million20.79% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$36 Million2.73% of portfolio
-
Invesco Ltd. Atlanta, GA3.16MShares$32.5 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$28.3 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT2.28MShares$23.5 Million0.04% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $404M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...